Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Change in Account Payables: 2020-2024

Historic Change in Account Payables for Relay Therapeutics (RLAY) over the last 5 years, with Sep 2024 value amounting to -$4.3 million.

  • Relay Therapeutics' Change in Account Payables fell 251.88% to -$4.3 million in Q3 2024 from the same period last year, while for Sep 2024 it was -$6.4 million, marking a year-over-year decrease of 228.70%. This contributed to the annual value of -$2.4 million for FY2023, which is 220.36% down from last year.
  • According to the latest figures from Q3 2024, Relay Therapeutics' Change in Account Payables is -$4.3 million, which was down 234.17% from $3.2 million recorded in Q2 2024.
  • Over the past 5 years, Relay Therapeutics' Change in Account Payables peaked at $4.6 million during Q3 2022, and registered a low of -$5.4 million during Q4 2023.
  • For the 3-year period, Relay Therapeutics' Change in Account Payables averaged around -$127,091, with its median value being $102,000 (2024).
  • Examining YoY changes over the last 5 years, Relay Therapeutics' Change in Account Payables showed a top increase of 828.46% in 2022 and a maximum decrease of 5,950.00% in 2022.
  • Over the past 5 years, Relay Therapeutics' Change in Account Payables (Quarterly) stood at $1.3 million in 2020, then surged by 89.63% to $2.4 million in 2021, then declined by 19.15% to $2.0 million in 2022, then tumbled by 373.21% to -$5.4 million in 2023, then plummeted by 251.88% to -$4.3 million in 2024.
  • Its Change in Account Payables was -$4.3 million in Q3 2024, compared to $3.2 million in Q2 2024 and $102,000 in Q1 2024.